Table 4.
Adverse events in the study population
Combination group (n=86) | Control group (n=41) | p value | ||
---|---|---|---|---|
Adverse events | ||||
Nausea | 30 (35%) | 13 (32%) | 0·87 | |
Diarrhoea | 34 (40%) | 18 (44%) | 0·54 | |
Increased alanine aminotransferase | 11 (13%) | 7 (17%) | 0·32 | |
Hyperbilirubinaemia | 4 (5%) | 3 (7%) | 0·54 | |
Sinus bradycardia | 3 (4%) | 1 (2%) | 0·77 | |
Fever | 32 (37%) | 16 (39%) | 0·73 | |
Serious adverse events | 0 | 1 (2%) | 0·15 | |
Duration of nausea, days | 2 (1–2) | 2 (1–2) | 0·80 | |
Duration of diarrhoea, days | 3 (3–3) | 3 (3–3) | 0·88 |